Skip to main content

Abbokinase Open-Cath Disease Interactions

There are 2 disease interactions with Abbokinase Open-Cath (urokinase).

Major

Thrombolytic agents (applies to Abbokinase Open-Cath) bleeding risks

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Cerebral Vascular Disorder, Retinal Hemorrhage, Hypertension, Infectious Endocarditis

The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110). Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy. Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy. Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.

Moderate

Urokinase (applies to Abbokinase Open-Cath) liver disease

Moderate Potential Hazard, Moderate plausibility.

Urokinase undergoes extensive clearance and degradation by the liver. The pharmacokinetic disposition of urokinase has not been fully determined, however it is expected that the half-life of urokinase would be prolonged in patients with hepatic impairment. Therapy with urokinase should be administered cautiously in patients with compromised hepatic function. Clinical monitoring of bleeding functions should be determined prior to initiation of therapy. Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.

Switch to professional interaction data

Abbokinase Open-Cath drug interactions

There are 154 drug interactions with Abbokinase Open-Cath (urokinase).

Abbokinase Open-Cath alcohol/food interactions

There is 1 alcohol/food interaction with Abbokinase Open-Cath (urokinase).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.